Abstract: A method for removing solutes while retaining suspension cells within a bioreactor includes positioning a suspension including cells within a predetermined region of the bioreactor and causing a flow rate across the suspension in the bioreactor, where the flow rate is selected to cause the solutes to move out of the bioreactor while the cells are maintained in the bioreactor.

Abstract: A microwell array specifically designed for culturing organoids is provided along with a system to enable automated imaging, identification, and isolation of individual organoids. The microwells of the microarray include a releasable cellraft that enables the automated release and transfer of selected organoids present on the cellrafts to a separate collection plate. Organoids grown on the microarray can be reliably tracked, imaged, and phenotypically analyzed by the instrument system in brightfield and fluorescence as they grow over time, then released and transferred fully intact for use in downstream applications. The use of the system is demonstrated using mouse hepatic and pancreatic organoids for single-organoid imaging, clonal organoid generation, parent organoid subcloning, and single-organoid RNA extraction for downstream gene expression or transcriptomic analysis.

Abstract: The disclosure relates to a method for releasing platelets from megakaryocytes contained in a fluid (F), the method being carried out by means of a system comprising two concentric cylinders, an inner cylinder comprising a cylindrical wall and a hollow outer cylinder located radially external to the inner cylinder, the outer cylinder comprising a cylindrical wall of a base at which the second cylinder is closed, the cylinders being separated by a space devoid of any mechanical parts, the space being intended to receive the fluid (F), the method comprising the following steps: supplying the space with a fluid (F) comprising megakaryocytes, rotating the inner cylinder about its axis, the outer cylinder being stationary, or moving the two cylinders in opposite directions about their axes, so as to generate an at least partially turbulent flow of fluid (F) in the space and obtain a second fluid (F?) enriched in platelets.

Abstract: A novel method of growing fungi is disclosed which uses an engineered artificial media and produces high density filamentous fungi biomats that can be harvested with a minimum of processing and from which fungal products such as antibiotics, proteins, and lipids can be isolated, the method resulting in lowered fungus cultivation costs for energy usage, oxygenation, water usage and waste stream production.

Abstract: Fungus with incorporated of heterologous ligninolytic enzyme to enhance effective conversion of lignocellulosic feedstocks to various chemical productions.

Abstract: Provided herein are compositions and methods for expression of functional bacterial type I fatty acid synthase in photosynthetic hosts for production of activated acyl-CoAs and for use in biofuel production.

Abstract: The present specification pertains to a microorganism and/or Escherichia coli and a use thereof, wherein the microorganism and/or Escherichia coli has 3-hydroxypropionic acid or 3-hydroxypropionate (3-HP) production ability, with a foreign 3-HP production gene inserted into the genomic DNA thereof, and has a use of measuring the production ability of the inserted 3-HP production gene.

Abstract: The invention described herein provides compositions and methods to maintain astrocytes in resting, enrichment and/or maturation, or activation states so that potential therapeutic agents treating diseases or conditions associated with reactive astrocytes can be identified.

Abstract: There is provided a masking sheet that is used for patterning cells or cell aggregates, which are formed on a culture surface. The masking sheet has the adhesive layer that is adhered to a culture surface, the support layer that is laminated on the adhesive layer to support the adhesive layer, and the opening portion that penetrates through the adhesive layer and the support layer and corresponds to a pattern of the cells or cell aggregates.

Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.

Abstract: A production method for highly proliferating cells or ectodermal progenitor cells, the production method including (i) preparing ectodermal cells which serve as a raw material, (ii) culturing the ectodermal cells which serve as the raw material in a medium containing a small-molecule signaling pathway inhibitor by bringing the inhibitor into contact with the ectodermal cells, and (iii) after the contact, performing additional culturing in a medium containing the inhibitor to obtain a culture containing highly proliferating cells that have higher cell proliferative ability than the ectodermal cells which serve as the raw material; highly proliferating cells having characteristics of ectodermal cells and proliferative ability that allows the number of the highly proliferating cells after more than 28 days of a culturing period during which the cells are brought into contact with a small-molecule signaling pathway inhibitor to be greater than 1.0 times the number of ectodermal cells.

Abstract: Provided are a modified tumor infiltrating lymphocyte (TIL) and a use thereof. Also provided is a method for culturing the TIL, comprising reducing the expression and/or decreasing the activity of NF-?B pathway inhibitory molecules of the TIL. Further provided is a method for preventing and/or treating tumors by using the TIL.

Abstract: The present disclosure provides methods for increasing the quantity and/or the ratios of erythroblasts, reticulocytes, and/or erythrocytes, or progenitors thereof, in which any of these cells express HbF (e.g. HbF+ and/or HbFhigh cells); increasing the quantity of erythrocytes and/or the ratios of erythrocytes to other related cells. The present disclosure relates, inter alia, to perturbagens and methods for directing a change in the cell state of a progenitor cell. The present disclosure further provides methods for treating diseases or disorders characterized by, for example, oxygen delivery deficiencies and/or reduced expression and/or activity of hemoglobin; abnormal erythron distribution and/or physiology or an erythrocyte deficiency; and diseases or disorders characterized by, at least, abnormal ratios and/or abnormal numbers of megakaryocytes, proplatelets, and/or platelets or immediate progenitors thereof.

Abstract: The invention of the current disclosure provides cell culture medium formulations useful for the culture of Natural Killer (NK) immune cells. Also included are methods of culture, cryopreservation, and transduction of NK cells comprising said culture medium formulations.

Abstract: This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.

Abstract: Systems, methods, and compositions for the introduction of mutations to the proximal promoter region of the HBG1 and HBG2 genes are provided. Also included are cells and compositions of cells bearing one or more synthetic alleles formed by the disclosed systems, methods, and compositions. This disclosure also provides a method of treating a subject by introducing the disclosed synthetic allele(s) into a cell of a subject.

Abstract: The present invention relates to the field of production of bioengineered tissues comprising skeletal muscle cells, particularly to compositions and methods for producing a plurality of skeletal muscle-committed progenitor cells from pluripotent stem cells and skeletal muscle cells differentiated therefrom. The present invention further provides a mass of skeletal muscle-committed progenitor cells and/or a mass of skeletal muscle cells, engineered tissue comprising same, and uses thereof.

Abstract: A microfluidic biomimetic fiber for cultured meat production and a preparation method therefor and use thereof are provided. The microfluidic biomimetic fiber has a shell-core structure; and an outer shell of the microfluidic biomimetic fiber is formed by cross-linking a polymer solution with cell non-adhesion, and an inner core wrapped by the outer shell is a hydrogel solution mixed with a seed cell. The present invention respectively introduces an inner phase fluid and an outer phase fluid into inner and outer phase channels of a microfluidic device, enables the two phase fluids in the channels of the microfluidic device to form a stable laminar flow structure by adjusting the flow velocities of the inner and outer phases, and extrudes same from a device outlet to obtain the biomimetic fiber.

Abstract: The present disclosure relates to a method for preparing cells for cancer treatment and a kit for cancer treatment comprising cells prepared by the method. The preparation method of the present disclosure can provide F cells, which, in spite of having no difference in the proliferative capacity compared with mesenchymal stem cells expressing cytosine deaminase that are harvested and used immediately after the culture, exhibit a very excellent tumor suppressive effect through the treatment together with 5-FC and induce a remarkable synergistic effect exceeding an effect from combinative treatment with an existing anticancer drug in cases of a combinative treatment with another anticancer drug. Therefore, the present disclosure can be utilized for a kit for cancer treatment comprising such F cells, and thus can be favorably used to maximize the effect of existing cancer treatments.

Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Abstract: Disclosed is a method of producing vascularized respiratory (airway and alveolar) organoids using blood vessel organoids. More particularly, vascularized respiratory (airway and alveolar) organoids with a vascular network are produced by fusing respiratory (airway and alveolar) organoids with blood vessel organoids to induce vascularization. The vascularized respiratory (airway and alveolar) organoids can have functions very similar to the human respiratory whole region, so they are expected to be transplanted into humans to treat respiratory related diseases or be used as an in vitro respiratory whole region model.

Abstract: Disclosed is a method of reprogramming somatic cells into induced pluripotent stem cells (iPSCs). Also disclosed is a method of producing, selecting, expanding, characterizing, and differentiating iPSCs. Further disclosed is a method of reprogramming somatic cells selected from the group consisting of fibroblasts IMR90, fibroblasts HFF-01, PBMC, CD3+ T cells and CD34+ hematopoietic stem cells (HSCs) into iPSCs.

Abstract: Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (iPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.

Abstract: Disclosed herein are cell genetically engineered cell for AAV production. The genetically engineered cell comprises molecular systems for temporal control of expression of genes required for AAV production. Also disclosed herein are methods of using genetically engineered cells for AAV production.

Abstract: This disclosure relates to methods and compositions for scaling up production of rAAV by cell cultures. In some aspects, the present disclosure relates to methods of transferring a plurality of transfection complexes to a bioreactor. Also provided are methods of improving production of recombinant adeno-associated virus (rAAV) particles by adding a second medium to the cell culture after transfection, thereby improving rAAV particle yield and reducing the amount of time needed to produce high levels of rAAV particles.

Abstract: Provided are methods of separating full capsid particles and empty capsid particles in a viral capsid preparation using an anion exchange medium. Methods may involve using a wash solution comprising a quaternary ammonium salt. Methods include applying a viral capsid preparation to an anion exchange medium, combined with multiple quaternary ammonium salt wash solutions.

Abstract: Described herein are the discovery and/or optimization of enzymes involved in the biosynthesis of olivetolic acid, divarinic acid, and analogs thereof.

Abstract: Methods of producing phytase variants useful for liberating phosphorous from phytate substrates, for reducing phytate levels in animal manure, for treating vegetable proteins, for improving the nutritional value of animal feed, for improving nutrient retention and/or digestibility in an animal, and for increasing weight gain, improving specific growth rate and/or improving Feed Conversion Ratio of an animal.

Abstract: Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.

Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.

Abstract: Provided herein are compositions for enabling natural adaptive spacer acquisition in CRISPR-Cas systems incapable of adaptation, e.g., non-adapting lactococcal CRISPR-Cas systems. Also provided are methods for using the compositions and products thereof to produce bacterial strains that are resistant, such as bacteriophage resistant, and/or evolved to have a desirable phenotype. Non-adapting CRISPR-Cas systems adapted according to the methods provided herein, and bacteria containing such adapted non-adapting CRISPR-Cas systems, are further provided. The compositions and methods provided herein allow for the controlled induction of natural spacer acquisition via adaptation in CRISPR-Cas systems that are fundamentally incapable of adaptation without modifying the features underlying the non-adapting behavior of the CRISPR-Cas system.

Abstract: The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and/or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

Abstract: Described herein are novel engineered peptides, viral vectors, and pharmaceutical compositions thereof, and uses of the same for increasing ?-GAL A expression and for the treatment of conditions associated with ?-GAL A deficiency, such as Fabry disease.

Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.

Abstract: The invention of the disclosure features compositions and methods for treating hereditary angioedema by introducing one or more alterations to a kallikrein B1 (KLKB1) polynucleotide in a cell. In particular embodiments, the invention provides a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a KLKB1 polynucleotide, where the modification is associated with reduced expression and/or reduced activity of the KLKB1 polypeptide encoded by the polynucleotide.

Abstract: The present invention pertains to a method for isolation and purification of nucleic acids from a stabilized sample or portion or fraction thereof, wherein the sample stabilization involved the use of at least one formaldehyde releaser and wherein the isolation of the nucleic acids from the stabilized sample or portion or fraction thereof involves the use of at least one cationic detergent during lysis.

Abstract: Disclosed herein are lysis reagents for lysing red blood cells, thereby releasing an analyte, such as RNA from a host or pathogen, in a form suitable for analysis. The reagent includes at least a buffer, a detergent and one or both of a chloride containing salt and an anti-coagulant. The reagent serves to lyse blood cells, protect the released analyte from degradation in the lysate, and is compatible with subsequent steps for analysis of the analyte such as target capture, amplification, detection, or sequencing.

Abstract: A method for selecting a functional antigen-binding protein. The method comprises the step of constructing an expression vector, by means of a phage display technique and/or a cell display technique, using a light chain or a fragment thereof of a reference antigen-binding protein with a known sequence and function, or a heavy chain or a fragment thereof of the reference antigen-binding protein, thereby selecting a functional antigen-binding protein that binds to the same epitope as the reference antigen-binding protein. Further provided is a functional antigen-binding protein obtained by means of the method.

Abstract: The invention provides a method for genetic analysis in individuals that reveals both the genetic sequences and chromosomal copy number of targeted and specific genomic loci in a single assay. The present invention further provide methods for the sensitive and specific detection of target gene sequences and gene expression profiles.

Abstract: Disclosed herein include systems, methods, compositions, and kits for preserving and/or recovering RNA from fixed and/or permeabilized cells, for example for single cell analysis. In some embodiments, the fixed and/or permeabilized cells are for measuring intracellular target (e.g., protein) expression.

Abstract: Provided are methods for resolving the relationship between unique user-designed and/or random synthetic DNA barcodes and a protein-coding mutated region of interest with enhanced accuracy that is amenable to short-read sequencing platforms. In addition, the methods introduce increased sequence divergence between mutational variants of a region of interest in order to enhance the resolvability of mutational variants within a mutagenic library when error-prone long-read sequencing platforms are used.

Abstract: The present invention provides a bos grunniens Lnc4047 and applications thereof, and belongs to the technical field of genetic engineering. The nucleotide sequence of the bos grunniens Lnc4047 is shown in SEQ ID No. 1. The regulation effect of Lnc4047 on myoblast proliferation and myoblast differentiation of bos grunniens is discovered in the present invention for the first time, that is, Lnc4047 inhibits myoblast proliferation, but promotes myoblast differentiation to a certain extent. This provides an important basis for understanding the muscle development mechanism of bos grunniens, and lays a theoretical foundation for rapidly developing a new high-quality breed of bos grunniens and improving its meat quality.

Abstract: Provided herein are methods and compositions for alteration of protein expression that can result in cell differentiation or production of proteins of biopharmaceutical relevance or engineered cells for use as therapeutic medicinal products. The compositions may comprise a saccharide, a nucleic acid molecule, and/or a polymeric material. The compositions and methods may promote or facilitate uptake of a nucleic acid by a cell. The compositions and methods may promote or facilitate differentiation of the cell.

Abstract: The invention involves the use of novel nucleic acid sequences to detect, modulate, ablate, inhibit or augment the transcription and therefore translation and expression of functionally-linked genes. The present disclosure is based on the novel finding that Transposable Element remnant (TEr) RNA or promoter non-processive transcripts (NPtx) have a high probability of aligning with high identity to transcriptional regulatory regions of functionally-linked genes, suggesting that they participate in beneficial transcriptional crosstalk.

Abstract: A nucleic acid molecule composed of a duplex and loop, in which one of the duplex strands, the guide strand, comprises a sequence chosen from SEQ ID NO. 1-4, and the other strand of the duplex, the passenger strand, is at least 80% complementary to the guide strand, wherein the nucleic acid molecule forms a hairpin structure in a cell.

Abstract: This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the brain. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.

Abstract: Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.

Abstract: This disclosure relates to novel microRNA-29 (miR-29) compounds, compositions comprising the same, and their use in therapy. In particular, provided herein are miR-29 compounds and compositions that are particularly effective and safe in the treatment of diseases that involve localised collagen dysregulation, such as tendon damage including tendinopathy, and tissue fibrosis including Peyronie's disease and Dupuytren's disease. Also provided are advantageous dosages and treatment regimens for miR-29 compounds.

Abstract: Provided herein are compounds for inhibiting peripheral myelin protein 22 (PMP22) mRNA. Also provided herein are methods of using such compounds for the treatment of Charcot-Marie-Tooth disease.

Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified intemucleoside linkage. In some embodiments, the disclosure provides oligomeric compounds and modified oligonucleotides comprising a central region in which purine-containing central region nucleosides are adjacent to methanesulfonyl phosphoramidate intemucleoside linkages.